Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Logan Capital Management Inc.

Logan Capital Management Inc. raised its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 236.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 42,065 shares of the company's stock after acquiring an additional 29,550 shares during the period. Logan Capital Management Inc.'s holdings in Dr. Reddy's Laboratories were worth $664,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of RDY. EverSource Wealth Advisors LLC raised its holdings in Dr. Reddy's Laboratories by 423.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after acquiring an additional 1,507 shares during the last quarter. Glass Jacobson Investment Advisors llc grew its stake in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock valued at $32,000 after buying an additional 1,600 shares during the period. POM Investment Strategies LLC grew its stake in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after buying an additional 1,820 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Dr. Reddy's Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after buying an additional 2,093 shares during the period. Finally, Allworth Financial LP grew its stake in shares of Dr. Reddy's Laboratories by 447.8% during the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company's stock valued at $41,000 after buying an additional 2,230 shares during the period. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Trading Up 0.3%

Shares of NYSE RDY traded up $0.05 during trading on Friday, hitting $14.44. 1,085,237 shares of the company traded hands, compared to its average volume of 1,491,451. Dr. Reddy's Laboratories Limited has a 1 year low of $12.26 and a 1 year high of $16.89. The company has a 50-day moving average price of $13.43 and a 200-day moving average price of $14.03. The firm has a market capitalization of $12.05 billion, a P/E ratio of 22.99 and a beta of 0.33. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The firm had revenue of $996.17 million during the quarter, compared to analysts' expectations of $83.70 billion. On average, equities analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.